Alumis Inc.(ALMS) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update -Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026- -Completed enrollment in Phase 2b LUMUS clinical trial for envudeucitinib in systemic lupus erythematosus (SLE); topline readout expected in Q3 2026- - Completed merger with ACELYRIN, Inc. to strengthen financial position and support advancement of late-stag ...